Review



col7a1 polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech col7a1 polyclonal antibody
    Identification of <t>COL7A1</t> as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).
    Col7a1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/col7a1+polyclonal+antibody/pmc11868062-64-7-11?v=Proteintech
    Average 93 stars, based on 14 article reviews
    col7a1 polyclonal antibody - by Bioz Stars, 2026-08
    93/100 stars

    Images

    1) Product Images from "COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma"

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2025.1543193

    Identification of COL7A1 as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).
    Figure Legend Snippet: Identification of COL7A1 as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).

    Techniques Used: Biomarker Assay, Expressing

    Validation of the COL7A1 expression levels. (A–C) Box plot of COL7A1 expression in LUAD and controls of GSE115002 (A) , GSE11072 (B) cohorts, and CCLE database (C) . (D) Immunohistochemical plots of COL7A1 in lung tissue downloaded from the HPA database, with LUAD tissue on the left and normal lung tissue on the right. (E, F) Expression of COL7A1 in LUAD determined by qPCR (E) and Western blot (F) . (*p < 0.05, **p < 0.01, ***p < 0.001).
    Figure Legend Snippet: Validation of the COL7A1 expression levels. (A–C) Box plot of COL7A1 expression in LUAD and controls of GSE115002 (A) , GSE11072 (B) cohorts, and CCLE database (C) . (D) Immunohistochemical plots of COL7A1 in lung tissue downloaded from the HPA database, with LUAD tissue on the left and normal lung tissue on the right. (E, F) Expression of COL7A1 in LUAD determined by qPCR (E) and Western blot (F) . (*p < 0.05, **p < 0.01, ***p < 0.001).

    Techniques Used: Expressing, Immunohistochemical staining, Western Blot

    Exploration of the association of COL7A1 expression with prognosis of LUAD patients. (A–C) The Kaplan-Meier curves of COL7A1 high expression and COL7A1 low expression groups in the LUAD patients of TCGA (A) , GSE72094 (B) , and GSE68465 (C) datasets. (D–F) Time-dependent ROC curves of the COL7A1 expression for predicting 1-, 3-, and 5-year survival in the TCGA (D) , GSE72094 (E) , and GSE68465 (F) datasets. (G) Univariate and multivariate Cox regression analysis of COL7A1 expression and clinical features including age, gender, clinical stage, and race.
    Figure Legend Snippet: Exploration of the association of COL7A1 expression with prognosis of LUAD patients. (A–C) The Kaplan-Meier curves of COL7A1 high expression and COL7A1 low expression groups in the LUAD patients of TCGA (A) , GSE72094 (B) , and GSE68465 (C) datasets. (D–F) Time-dependent ROC curves of the COL7A1 expression for predicting 1-, 3-, and 5-year survival in the TCGA (D) , GSE72094 (E) , and GSE68465 (F) datasets. (G) Univariate and multivariate Cox regression analysis of COL7A1 expression and clinical features including age, gender, clinical stage, and race.

    Techniques Used: Expressing

    Exploration of the biological significance of different COL7A1 expression groups. (A) The top 10 KEGG pathways with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (B) Five important KEGG pathways were activated in the high COL7A1 expression group based on GSEA. (C) The top 5 GO terms with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (D) Five important GO terms were activated in the high COL7A1 expression group based on GSEA.
    Figure Legend Snippet: Exploration of the biological significance of different COL7A1 expression groups. (A) The top 10 KEGG pathways with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (B) Five important KEGG pathways were activated in the high COL7A1 expression group based on GSEA. (C) The top 5 GO terms with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (D) Five important GO terms were activated in the high COL7A1 expression group based on GSEA.

    Techniques Used: Expressing

    The landscape of immune cell infiltration between different groups. (A–D) Box plot of tumor purity (A) , immune (B) , stromal (C) , and ESTIMATE (D) scores in different COL7A1 expression groups based on the GSE68465 dataset. (E, F) TStacked plot of 22 immune cell types in each sample of TCGA-LUAD (E) and GSE68465 (F) cohorts. (G, H) The 22 immune cell infiltration in the high COL7A1 expression and low COL7A1 expression groups of TCGA-LUAD (G) and GSE68465 (H) cohorts. (*p < 0.05, **p < 0.01, ***p < 0.001)
    Figure Legend Snippet: The landscape of immune cell infiltration between different groups. (A–D) Box plot of tumor purity (A) , immune (B) , stromal (C) , and ESTIMATE (D) scores in different COL7A1 expression groups based on the GSE68465 dataset. (E, F) TStacked plot of 22 immune cell types in each sample of TCGA-LUAD (E) and GSE68465 (F) cohorts. (G, H) The 22 immune cell infiltration in the high COL7A1 expression and low COL7A1 expression groups of TCGA-LUAD (G) and GSE68465 (H) cohorts. (*p < 0.05, **p < 0.01, ***p < 0.001)

    Techniques Used: Expressing

    Validation of COL7A1 expression in predicting the clinical benefit of immunotherapy. (A) IC50 values of the 11 drugs in the COL7A1-H and COL7A1-L groups. (B) The expression levels of immune checkpoint genes in different COL7A1 expression groups. (C) . Correlation analysis of immune checkpoint genes and COL7A1 expression (the data conformed to normal distribution, employing pearson correlation analysis) (D–I) Violin plots of TIDE (D) , Exclusion (E) , Dysfunction (F) , MDSC (G) , CAF (H) , and CD274 (I) scores in different COL7A1 expression groups.
    Figure Legend Snippet: Validation of COL7A1 expression in predicting the clinical benefit of immunotherapy. (A) IC50 values of the 11 drugs in the COL7A1-H and COL7A1-L groups. (B) The expression levels of immune checkpoint genes in different COL7A1 expression groups. (C) . Correlation analysis of immune checkpoint genes and COL7A1 expression (the data conformed to normal distribution, employing pearson correlation analysis) (D–I) Violin plots of TIDE (D) , Exclusion (E) , Dysfunction (F) , MDSC (G) , CAF (H) , and CD274 (I) scores in different COL7A1 expression groups.

    Techniques Used: Expressing



    Similar Products

    col7a1  (TargetMol)
    93
    TargetMol col7a1
    Col7a1, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/col7a1+polyclonal+antibody/pm40752536-77-11-5?v=TargetMol
    Average 93 stars, based on 1 article reviews
    col7a1 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    col7a1 polyclonal antibody  (Proteintech)
    93
    Proteintech col7a1 polyclonal antibody
    Identification of <t>COL7A1</t> as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).
    Col7a1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/col7a1+polyclonal+antibody/pmc11868062-64-7-11?v=Proteintech
    Average 93 stars, based on 1 article reviews
    col7a1 polyclonal antibody - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    rabbit polyclonal antibody against human c7  (Atlas Antibodies)
    91
    Atlas Antibodies rabbit polyclonal antibody against human c7
    Identification of <t>COL7A1</t> as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).
    Rabbit Polyclonal Antibody Against Human C7, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/col7a1+polyclonal+antibody/pm37302620-177-5-12?v=Atlas+Antibodies
    Average 91 stars, based on 1 article reviews
    rabbit polyclonal antibody against human c7 - by Bioz Stars, 2026-08
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Identification of COL7A1 as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: Identification of COL7A1 as a BM-related key biomarker in LUAD. (A) Univariate Cox regression analysis of 12 candidate genes. (B–D) The expression levels of three prognosis-associated genes, including COL7A1 (B) , MMP1 (C) , and LAMA3 (D) , in LUAD samples and controls of the TCGA dataset (*p < 0.05, **p < 0.01, ***p < 0.001).

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Biomarker Assay, Expressing

    Validation of the COL7A1 expression levels. (A–C) Box plot of COL7A1 expression in LUAD and controls of GSE115002 (A) , GSE11072 (B) cohorts, and CCLE database (C) . (D) Immunohistochemical plots of COL7A1 in lung tissue downloaded from the HPA database, with LUAD tissue on the left and normal lung tissue on the right. (E, F) Expression of COL7A1 in LUAD determined by qPCR (E) and Western blot (F) . (*p < 0.05, **p < 0.01, ***p < 0.001).

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: Validation of the COL7A1 expression levels. (A–C) Box plot of COL7A1 expression in LUAD and controls of GSE115002 (A) , GSE11072 (B) cohorts, and CCLE database (C) . (D) Immunohistochemical plots of COL7A1 in lung tissue downloaded from the HPA database, with LUAD tissue on the left and normal lung tissue on the right. (E, F) Expression of COL7A1 in LUAD determined by qPCR (E) and Western blot (F) . (*p < 0.05, **p < 0.01, ***p < 0.001).

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Expressing, Immunohistochemical staining, Western Blot

    Exploration of the association of COL7A1 expression with prognosis of LUAD patients. (A–C) The Kaplan-Meier curves of COL7A1 high expression and COL7A1 low expression groups in the LUAD patients of TCGA (A) , GSE72094 (B) , and GSE68465 (C) datasets. (D–F) Time-dependent ROC curves of the COL7A1 expression for predicting 1-, 3-, and 5-year survival in the TCGA (D) , GSE72094 (E) , and GSE68465 (F) datasets. (G) Univariate and multivariate Cox regression analysis of COL7A1 expression and clinical features including age, gender, clinical stage, and race.

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: Exploration of the association of COL7A1 expression with prognosis of LUAD patients. (A–C) The Kaplan-Meier curves of COL7A1 high expression and COL7A1 low expression groups in the LUAD patients of TCGA (A) , GSE72094 (B) , and GSE68465 (C) datasets. (D–F) Time-dependent ROC curves of the COL7A1 expression for predicting 1-, 3-, and 5-year survival in the TCGA (D) , GSE72094 (E) , and GSE68465 (F) datasets. (G) Univariate and multivariate Cox regression analysis of COL7A1 expression and clinical features including age, gender, clinical stage, and race.

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Expressing

    Exploration of the biological significance of different COL7A1 expression groups. (A) The top 10 KEGG pathways with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (B) Five important KEGG pathways were activated in the high COL7A1 expression group based on GSEA. (C) The top 5 GO terms with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (D) Five important GO terms were activated in the high COL7A1 expression group based on GSEA.

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: Exploration of the biological significance of different COL7A1 expression groups. (A) The top 10 KEGG pathways with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (B) Five important KEGG pathways were activated in the high COL7A1 expression group based on GSEA. (C) The top 5 GO terms with significant differences between the high COL7A1 expression and low COL7A1 expression groups. (D) Five important GO terms were activated in the high COL7A1 expression group based on GSEA.

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Expressing

    The landscape of immune cell infiltration between different groups. (A–D) Box plot of tumor purity (A) , immune (B) , stromal (C) , and ESTIMATE (D) scores in different COL7A1 expression groups based on the GSE68465 dataset. (E, F) TStacked plot of 22 immune cell types in each sample of TCGA-LUAD (E) and GSE68465 (F) cohorts. (G, H) The 22 immune cell infiltration in the high COL7A1 expression and low COL7A1 expression groups of TCGA-LUAD (G) and GSE68465 (H) cohorts. (*p < 0.05, **p < 0.01, ***p < 0.001)

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: The landscape of immune cell infiltration between different groups. (A–D) Box plot of tumor purity (A) , immune (B) , stromal (C) , and ESTIMATE (D) scores in different COL7A1 expression groups based on the GSE68465 dataset. (E, F) TStacked plot of 22 immune cell types in each sample of TCGA-LUAD (E) and GSE68465 (F) cohorts. (G, H) The 22 immune cell infiltration in the high COL7A1 expression and low COL7A1 expression groups of TCGA-LUAD (G) and GSE68465 (H) cohorts. (*p < 0.05, **p < 0.01, ***p < 0.001)

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Expressing

    Validation of COL7A1 expression in predicting the clinical benefit of immunotherapy. (A) IC50 values of the 11 drugs in the COL7A1-H and COL7A1-L groups. (B) The expression levels of immune checkpoint genes in different COL7A1 expression groups. (C) . Correlation analysis of immune checkpoint genes and COL7A1 expression (the data conformed to normal distribution, employing pearson correlation analysis) (D–I) Violin plots of TIDE (D) , Exclusion (E) , Dysfunction (F) , MDSC (G) , CAF (H) , and CD274 (I) scores in different COL7A1 expression groups.

    Journal: Frontiers in Pharmacology

    Article Title: COL7A1 indicates crucial potential as a basal membrane-related prognostic biomarker and therapeutic target in lung adenocarcinoma

    doi: 10.3389/fphar.2025.1543193

    Figure Lengend Snippet: Validation of COL7A1 expression in predicting the clinical benefit of immunotherapy. (A) IC50 values of the 11 drugs in the COL7A1-H and COL7A1-L groups. (B) The expression levels of immune checkpoint genes in different COL7A1 expression groups. (C) . Correlation analysis of immune checkpoint genes and COL7A1 expression (the data conformed to normal distribution, employing pearson correlation analysis) (D–I) Violin plots of TIDE (D) , Exclusion (E) , Dysfunction (F) , MDSC (G) , CAF (H) , and CD274 (I) scores in different COL7A1 expression groups.

    Article Snippet: In this experiment, the primary antibody was COL7A1 Polyclonal Antibody (19799-1-AP, Proteintech Group, Wuhan, China) and GAPDH Antibody (60004-1-Ig, Proteintech Group, Wuhan, China), and the secondary antibody was horseradase labeling of goat with anti-rabbit IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China) and horseradase labeling of goat anti-mouse IgG 1:1,000 (ZB-2301-0.1mL, Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., Beijing, China).

    Techniques: Expressing